Shandong Sanyuan Biotechnology Co.Ltd. (301206) - Net Assets
Based on the latest financial reports, Shandong Sanyuan Biotechnology Co.Ltd. (301206) has net assets worth CN¥4.31 Billion CNY (≈ $631.41 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥4.48 Billion ≈ $655.85 Million USD) and total liabilities (CN¥166.97 Million ≈ $24.43 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Shandong Sanyuan Biotechnology Co.Ltd. (301206) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥4.31 Billion |
| % of Total Assets | 96.27% |
| Annual Growth Rate | 59.69% |
| 5-Year Change | 780.78% |
| 10-Year Change | 10516.81% |
| Growth Volatility | 92.26 |
Shandong Sanyuan Biotechnology Co.Ltd. - Net Assets Trend (2013–2024)
This chart illustrates how Shandong Sanyuan Biotechnology Co.Ltd.'s net assets have evolved over time, based on quarterly financial data. Also explore Shandong Sanyuan Biotechnology Co.Ltd. (301206) total assets for the complete picture of this company's asset base.
Annual Net Assets for Shandong Sanyuan Biotechnology Co.Ltd. (2013–2024)
The table below shows the annual net assets of Shandong Sanyuan Biotechnology Co.Ltd. from 2013 to 2024. For live valuation and market cap data, see 301206 company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥4.49 Billion ≈ $657.20 Million |
-1.03% |
| 2023-12-31 | CN¥4.54 Billion ≈ $664.06 Million |
-1.79% |
| 2022-12-31 | CN¥4.62 Billion ≈ $676.16 Million |
+342.04% |
| 2021-12-31 | CN¥1.05 Billion ≈ $152.96 Million |
+105.00% |
| 2020-12-31 | CN¥509.91 Million ≈ $74.62 Million |
+46.46% |
| 2019-12-31 | CN¥348.15 Million ≈ $50.95 Million |
+93.94% |
| 2018-12-31 | CN¥179.52 Million ≈ $26.27 Million |
+55.01% |
| 2017-12-31 | CN¥115.81 Million ≈ $16.95 Million |
+33.66% |
| 2016-12-31 | CN¥86.64 Million ≈ $12.68 Million |
+104.81% |
| 2015-12-31 | CN¥42.30 Million ≈ $6.19 Million |
+59.06% |
| 2014-12-31 | CN¥26.60 Million ≈ $3.89 Million |
+1.98% |
| 2013-12-31 | CN¥26.08 Million ≈ $3.82 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Shandong Sanyuan Biotechnology Co.Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 70570529153.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥705.65 Million | 15.71% |
| Common Stock | CN¥202.33 Million | 4.50% |
| Other Components | CN¥3.58 Billion | 79.78% |
| Total Equity | CN¥4.49 Billion | 100.00% |
Shandong Sanyuan Biotechnology Co.Ltd. Competitors by Market Cap
The table below lists competitors of Shandong Sanyuan Biotechnology Co.Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Johns LYNG Group Ltd
AU:JLG
|
$806.21 Million |
|
Costar Group Co Ltd
SHE:002189
|
$806.48 Million |
|
Shanghai Maling Aquarius Co Ltd
SHG:600073
|
$806.85 Million |
|
Tae Kwang Corporation
KQ:023160
|
$807.25 Million |
|
RIAMB (Beijing) Tech Dvlp Co
SHG:603082
|
$806.18 Million |
|
Suzhou Longway Electronic Machinery Co. Ltd. A
SHE:301202
|
$806.17 Million |
|
Shandong Xiantan Co Ltd
SHE:002746
|
$805.91 Million |
|
Time Publishing and Media Co Ltd Class A
SHG:600551
|
$805.67 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shandong Sanyuan Biotechnology Co.Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 4,538,022,505 to 4,491,208,199, a change of -46,814,306 (-1.0%).
- Net income of 104,951,340 contributed positively to equity growth.
- Dividend payments of 80,895,868 reduced retained earnings.
- Share repurchases of 17,604,440 reduced equity.
- Other factors decreased equity by 53,265,338.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥104.95 Million | +2.34% |
| Dividends Paid | CN¥80.90 Million | -1.8% |
| Share Repurchases | CN¥17.60 Million | -0.39% |
| Other Changes | CN¥-53.27 Million | -1.19% |
| Total Change | CN¥- | -1.03% |
Book Value vs Market Value Analysis
This analysis compares Shandong Sanyuan Biotechnology Co.Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.22x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 31.40x to 1.22x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | CN¥0.87 | CN¥27.23 | x |
| 2014-12-31 | CN¥0.89 | CN¥27.23 | x |
| 2015-12-31 | CN¥0.67 | CN¥27.23 | x |
| 2016-12-31 | CN¥0.98 | CN¥27.23 | x |
| 2017-12-31 | CN¥0.83 | CN¥27.23 | x |
| 2018-12-31 | CN¥1.22 | CN¥27.23 | x |
| 2019-12-31 | CN¥1.72 | CN¥27.23 | x |
| 2020-12-31 | CN¥2.52 | CN¥27.23 | x |
| 2021-12-31 | CN¥5.17 | CN¥27.23 | x |
| 2022-12-31 | CN¥22.84 | CN¥27.23 | x |
| 2023-12-31 | CN¥22.35 | CN¥27.23 | x |
| 2024-12-31 | CN¥22.25 | CN¥27.23 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shandong Sanyuan Biotechnology Co.Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 2.34%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 14.72%
- • Asset Turnover: 0.15x
- • Equity Multiplier: 1.07x
- Recent ROE (2.34%) is below the historical average (18.48%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 1.36% | 1.85% | 0.43x | 1.73x | CN¥-2.25 Million |
| 2014 | 1.94% | 2.57% | 0.35x | 2.15x | CN¥-2.14 Million |
| 2015 | 4.95% | 5.08% | 0.60x | 1.63x | CN¥-2.08 Million |
| 2016 | 16.29% | 15.68% | 0.70x | 1.48x | CN¥5.38 Million |
| 2017 | 16.15% | 15.46% | 0.67x | 1.56x | CN¥7.12 Million |
| 2018 | 37.93% | 23.30% | 1.04x | 1.56x | CN¥50.14 Million |
| 2019 | 39.15% | 28.59% | 0.91x | 1.50x | CN¥101.49 Million |
| 2020 | 45.61% | 29.70% | 1.00x | 1.53x | CN¥181.58 Million |
| 2021 | 51.22% | 31.96% | 1.03x | 1.56x | CN¥430.88 Million |
| 2022 | 3.54% | 24.25% | 0.14x | 1.05x | CN¥-298.39 Million |
| 2023 | 1.30% | 11.79% | 0.10x | 1.06x | CN¥-394.93 Million |
| 2024 | 2.34% | 14.72% | 0.15x | 1.07x | CN¥-344.17 Million |
Industry Comparison
This section compares Shandong Sanyuan Biotechnology Co.Ltd.'s net assets metrics with peer companies in the Confectioners industry.
Industry Context
- Industry: Confectioners
- Average net assets among peers: $887,422,207
- Average return on equity (ROE) among peers: 3.21%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shandong Sanyuan Biotechnology Co.Ltd. (301206) | CN¥4.31 Billion | 1.36% | 0.04x | $806.19 Million |
| Guangxi Guitang Group Co Ltd (000833) | $767.94 Million | 3.91% | 0.74x | $3.72 Billion |
| Nanning Sugar Industry Co Ltd (000911) | $207.75 Million | 13.16% | 17.18x | $335.66 Million |
| Baotou Huazi Industry Co Ltd (600191) | $1.69 Billion | -7.43% | 0.06x | $901.20 Million |
About Shandong Sanyuan Biotechnology Co.Ltd.
Shandong Sanyuan Biotechnology Co.,Ltd. engages in the research and development, production, and sale of erythritol and compound sugar products in China. Its products are used in table sugar, flavored sugar, and beverages; candy and chocolate food; baked food; health food; medical supplies; cosmetic products; chemical products; and other applications. The company exports its products to Europe, t… Read more